



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Juliet Caroline Switzer  
Group Art Unit : 1634  
Applicants : Ulrich Brinkmann et al.  
Application No. : 10/627,253  
Confirmation No. : 4194  
Filed : July 24, 2003  
For : POLYMORPHISMS IN THE HUMAN GENE FOR THE  
MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1  
(MRP-1) AND THEIR USE IN DIAGNOSTIC AND  
THERAPEUTIC APPLICATIONS

New York, New York  
August 22, 2006

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

**Sir:**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record  
the following documents, copies of which are submitted herewith.\*

---

\* For the Examiner's convenience, applicants have also enclosed a completed Form PTO/SB/08A, listing these documents. Applicants have also enclosed a copy of the PCT International Search Report.

Application No. 10/627,253  
Information Disclosure Statement dated August 22, 2006

Foreign Patent Documents

<u>Publication No.</u>	<u>Publication Date</u>
WO 94/29469	December 22, 1994
WO 97/00957	January 9, 1997

OTHER DOCUMENTS

Anderson, "Human Gene Therapy", *Science*, 256:808-813 (1992).

Bakos et al., "Functional Multidrug Resistance Protein (MRP1) Lacking The N-Terminal Transmembrane Domain," *Journal of Biological Chemistry*, 273(27):32167-32175 (1998).

Berry et al., "A Prototype Computer System For *De Novo* Protein Design," *Biochemical Society Transactions*, 2(4):1033-1036 (1994).

Bertz et al., "Use of *In Vitro* and *In Vivo* Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions," *Clinical Pharmacokinetics*, 32(3):210-258 (1997).

Borst et al., "The Multidrug Resistance Protein Family," *Biochimica et Biophysica Acta*, 1461:347-357 (1999).

Borst et al., "A Family of Drug Transporters: The Multidrug Resistance-Associated Proteins," *Journal of National Cancer Institute*, 92(16):1295-1302 (2000).

Campling et al., "Expression of the *MRP* and *MDR1* Multidrug Resistance Genes in Small Cell Lung Cancer," *Clinical Cancer Research*, 3(1):115-122 (1997).

Chow et al. "Rising Incidence of Renal Cell Cancer in the United States," *JAMA*, 281(17):1628-1631 (1999).

Cole et al., "Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP," *BioEssays*, 20(11):931-940 (1998).

Cole et al., "Pharmacological Characterization of Multidrug Resistant MRP-transfected Human Tumor Cells," *Cancer Research*, 54:5902-5910 (1994).

Database EMBL Online EBI; Seq ID No.: 75, Database Accession No. AC026452, XP002217455 abstract (2000).

Database EMBL Online EBI; Database Accession No.: AC026452, Doe Joint Genome Institute: "Sequencing of Human Chromosome 16" XP002241553 for SEQ ID NOs: 171 and 172 Abstract (2000).

D'Hondt et al., "Retrovirus-Mediated Gene Transfer of the Multidrug Resistance-Associated Protein (MRP) cDNA Protects Cells from Chemotherapeutic Agents," *Human Gene Therapy*, 8(15):1745-1751 (1997).

Dörner et al., "The Synthesis of Peptidomimetic Combinatorial Libraries Through Successive Amide Alkylations," *Bioorganic and Medicinal Chemistry*, 4(5):709-715 (1996).

Engel et al., "Prediction of CYP2D6-Mediated Polymorphic Drug Metabolism (Sparteine Type) Based On In Vitro Investigations," *Journal of Chromatography B: Biomedical Applications*, 678:93-103 (1996).

Evers et al., "Inhibitory Effect Of The Reversal Agents V-104, GF120918 And Pluronic L61 On MDR1 Pgp-, MRP1- And MR2-Mediated Transport," *British Journal of Cancer*, 83(3):366-374 (2000).

Fassina et al., "Identification of Interactive Sites of Proteins and Protein Receptors by Computer-Assisted Searches for Complementary Peptide Sequences," *Immunomethods*, 5:114-120 (1994).

Filipits et al., "Immunocytochemical Detection Of The Multidrug Resistance-Associated Protein And P-Glycoprotein In Acute Myeloid Leukemia: Impact Of Antibodies, Sample Source And Disease Status," *Leukemia*, 11(7):1073-1077 (1997).

Flens et al., "Immunochemical Detection Of The Multidrug Resistance-Associated Protein MRP In Human Multidrug-Resistant Tumor Cells By Monoclonal Antibodies," *Cancer Research*, 54(17):4557-4563 (1994).

Galfrè et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," *Methods in Enzymology*, 73:3-46 (1981).

Giordano et al., "Intracoronary Gene Transfer Of Fibroblast Growth Factor-5 Increases Blood Flow And Contractile Function In An Ischemic Region Of The Heart," *Nature Medicine*, 2(5):534-539 (1996).

Grant et al., "Analysis of the Intron-Exon Organization of the Human Multidrug-Resistance Protein Gene (*MRP*) and Alternative Splicing of Its mRNA," *Genomics*, 45(2):368-378 (1997).

Heath et al., "Hypertension, Diuretics, and Antihypertensive Medications as Possible Risk Factors for Renal Cell Cancer," *American Journal of Epidemiology*, 145(7):607-613 (1997).

Heijn et al., "Anthracyclines Modulate Multidrug Resistance Protein (MRP) Mediated Organic Anion Transport," *Biochimica et Biophysica Acta*, 1326: 12-22 (1997).

Hipfner et al., "Monoclonal Antibodies that Inhibit the Transport Function of the 190-kDa Multidrug Resistance Protein, MRP," *Journal of Biological Chemistry*, 274(22):15420-15426 (1999).

Hipfner et al., "Detection of the Mr190,000 Multidrug Resistance Protein, MRP, with Monoclonal Antibodies," *Cancer Research*, 54(22):5788-5792.

Hipfner et al., "Membrane Topology of the Multidrug Resistance Protein (MRP)," *Journal of Biological Chemistry*, 272(38):23623-23630 (1997).

Hipfner et al. "Structural, Mechanistic And Clinical Aspects Of MRP1," *Biochimica et Biophysica Acta*, 1461:359-376 (1999).

Hoffman et al., "Rapid Protein Structure Classification Using One-Dimensional Structure Profiles On The Bioscan Parallel Computer," *CABIOS*, 11(6):675-679 (1995).

Hrycyna et al., Mechanism of Action of Human P-glycoprotein ATPase Activity," *Journal of Biological Chemistry*, 273(27):16631-16634 (1998).

Isner et al, "Clinical Evidence Of Angiogenesis After Arterial Gene Transfer Of phVEGF165 In Patient With Ischaemic Limb," *Lancet*, 348(10):370-374 (1996).

Jedlitschky et al., "ATP-Dependent Transport Of Bilirubin Glucuronides By The Multidrug Resistance Protein MRP-1 And Its Hepatocyte Canalicular Isoform MRP2," *Biochemical Journal*, 327:305-310 (1997).

Jounaïdi et al., "Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?," *Biochemical and Biophysical Research Communication*, 221:466-470 (1996).

Klein et al., "An Inventory Of The Human ABC Proteins," *Biochimica et Biophysica Acta*, 1461:237-262 (1999).

Kohler et al., "Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity," *Nature*, 256:495-497 (1975).

Levine, "Acquired Cystic Kidney Disease," *Radiologic Clinics of North America*, 34(5):947-964 (1996).

Linehan et al., "Identification of The Von Hippel-Lindau (VHL) Gene," *JAMA*, 273(7):564-570 (1995).

Loe et al., "ATP-Dependent Transport of Aflatoxin B1 and its Glutathione Conjugates by the Product of the Multidrug Resistance Protein (MRP) Gene," *Molecular Pharmacology*, 51(6):1034-1041 (1997).

Loftus et al., "Genome Duplications and Other Features in 12 MB of DNA Sequence from Human Chromosome 16p and 16q," *Genomics*, 60(3):295-308 (1999).

Longueux et al., "Candidate Genetic Modifiers of Individual Susceptibility to Renal Cell Carcinoma: A Study of Polymorphic Human Xenobiotic-Metabolizing Enzymes," *Cancer Research*, 59:2903-2908 (1999).

Machiels et al., "Retrovirus-Mediated Gene Transfer of the Human Multidrug Resistance-Associated Protein into Hematopoietic Cells Protects Mice from Chemotherapy-Induced Leukopenia," *Human Gene Therapy*, 10(5): 801-811 (1999).

Malmberg et al., "BIAcore As A Tool In Antibody Engineering," *Journal of Immunological Methods*, 183:7-13 (1995).

Marshall, "Getting The Right Drug Into The Right Patient," *Nature Biotechnology*, 15(12):1249-1252 (1997).

Marshall, "Laying The Foundations For Personalized Medicines," *Nature Biotechnology*, 15(10):954-957 (1997).

Meyer et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism," *Annual Review of Pharmacology and Toxicology*, 37:269-296 (1997).

Meyer, "Overview of Enzymes of Drug Metabolism," *Journal of Pharmacokinetics and Biopharmaceutics*, 24(5):449-459 (1996).

Monge et al., "Computer Modeling of Protein Folding: Conformational and Energetic Analysis of Reduced and Detailed Proteins Models," *Journal of Molecular Biology*, 247(5):995-1012 (1995).

Mouellic et al., "Targeted Replacement Of The Homeobox Gene *Hox-3.1* By The *Escherichia Coli LacZ* In Mouse Chimeric Embryos," *PNAS*, 87:4712-4716 (1990).

Mühlhauser et al., "VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," *Circulation Research*, 77:1077-1086 (1995).

Nooter et al., "Molecular Mechanisms of Multidrug Resistance in Cancer Chemotherapy," *Pathology Research and Practice*, 192(7):768-780 (1996).

Norris et al., "Expression Of The Gene For Multidrug-Resistance-Associated Protein And Outcome In Patients With Neuroblastoma," *New England Journal of Medicine*, 334(4):231-238 (1996).

Olszewski et al., "Folding Simulations and Computer Redesign of Protein A Three-Helix Bundle Motifs," *Proteins: Structure, Function, and Genetics*, 25(3):286-299 (1996)

Ostresh et al., "Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries," *Methods in Enzymology*, 267:220-234 (1996).

Ozama, "Strategic Proposals For Avoiding Toxic Interactions With Drugs For Clinical Use During Development And After Marketing Of A New Drug – Proposals For Designing Non-Clinical And Clinical Studies – Is The Non-Clinical Study Useful?," *Journal of Toxicological Sciences*, 21(5):323-329 (1996).

Pabo et al., "Computer-Aided Model-Building Strategies for Protein Design," *Biochemistry*, 25(20):5987-5991 (1986).

Perdu et al., "Identification of Novel Polymorphisms in the pM5 and MRP1 (ABCC1) Genes at Locus 16p13.1 and Exclusion of Both Genes as Responsible for Pseudoxanthoma Elasticum," *Human Mutation*, 17(1):74-75 (2001).

Priebe et al., "Doxorubicin – and Daunorubicin-Glutathione Conjugates, but not Unconjugated Drugs, Competitively Inhibit Leukotriene C4 Transport Mediated by MRP/GS-X Pump," *Biochemical and Biophysical Research Communication*, 247(3):859-863 (1998).

Ramsay, "DNA Chips: State-of-the Art," *Nature Biotechnology*, 16:40-44 (1998).

Rao et al., "Choroid Plexus Epithelial Expression Of *MDR1* P Glycoprotein And Multidrug Resistance-Associated Protein Contribute To The Blood-Cerebrospinal-Fluid Drug-Permeability Barrier," *PNAS*, 96:3900-3905 (1999).

Rappa et al., "New Insights into the Biology and Pharmacology of the Multidrug Resistance Protein (MRP) from the Gene Knockout Models," *Biochemical Pharmacology*, 58(4):557-562 (1999).

Renouf et al., "Molecular Modelling Of Glycoproteins By Homology With Non-Glycosylated Protein Domains, Computer Simulated Glycosylation And Molecular Dynamics," *Glycoimmunology*, 376:37-45 (1995).

Rose et al., "Three-Dimensional Structures of HIV-1 and SIV Protease Product Complexes," *Biochemistry*, 35:12933-12944 (1996).

Ross et al., "High level multiplex genotyping by MALDI-TOF mass spectrometry," *Nature Biotechnology*, 16:1347-1351 (1998).

Rutenber et al., "A New Class of HIV-1 Protease Inhibitor: The Crystallographic Structure, Inhibition and Chemical Synthesis of an Aminimide Peptide Isostere," *Bioorganic and Medicinal Chemistry*, 4(9):1545-1558 (1996).

Schaper et al., "Molecular Mechanisms of Coronary Collateral Vessel Growth," *Circulation Research*, 79:911-919 (1996).

Schaper et al., "Therapeutic Targets In Cardiovascular Disorders," *Current Opinion in Biotechnology*, 7(6):635-640 (1996).

Schier et al., "Efficient *In Vitro* Affinity Maturation Of Phage Antibodies Using Biacore Guided Selections," *Human Antibodies and Hybridomas*, 7(3):97-105 (1996).

Schlehofer et al., "International Renal-Cell-Cancer Study IV. The Role of Medical and Family History," *International Journal of Cancer*, 66(6):723-726 (1996).

Schneider et al., "ATP-Binding-Cassette (ABC) Transport Systems: Functional And Structural Aspects Of The ATP-Hydrolyzing Subunits/Domains," *FEMS Microbiology Reviews*, 22:1-20 (1998).

Shimer et al., "Ligase Chain Reaction," *Methods in Molecular Biology*, 46:269-278 (1995).

Stewart et al., "Reduction of Expression of the Multidrug Resistance Protein (MRP) in Human Tumor Cells by Antisense Phosphorothioate Oligonucleotides," *Biochemical Pharmacology*, 51(4):461-469 (1996).

Stride et al., "Pharmacological Characterization of the Murine and Human Orthologs of Multidrug-Resistance Protein in Transfected Human Embryonic Kidney Cells," *Molecular Pharmacology*, 52:344-353 (1997).

Sullivan et al., "The Expression of Drug Resistance Gene Products During the Progressional of Human Prostrate Cancer," *Clinical Cancer Research*, 4(6):1393-1403 (1998).

Takebayashi et al., "The Expression of Multidrug Resistance Protein in Human Gastrointestinal Tract Carcinomas," *Cancer*, 82(4):661-666 (1998).

Ueda et al., "How Does P-Glycoprotein Recognize Its Substrates?," *Seminars in Cancer Biology*, 8(3):151-159 (1997).

Walker et al., "Distantly Related Sequences In The A- And B-Subunits Of ATP Synthase, Myosin, Kinases And Other ATP-Requiring Enzymes And A Common Nucleotide Binding Fold," *The EMBO Journal*, 1(8):945-951 (1982).

Wang et al., "Second-Generation Adenovirus Vectors," *Nature Medicine*, 2(6):714-716 (1996).



West et al, "Interpatient Variability: Genetic Predisposition and Other Genetic Factors," *Journal of Clinical Pharmacology*, 37(7):635-648 (1997).

Wijnholds et al., "Increased Sensitivity To Anticancer Drugs And Decreased Inflammatory Response In Mice Lacking The Multidrug Resistance-Associated Protein," *Nature Medicine*, 3(11):1275-1279 (1991).

Williams et al., "Introduction Of Foreign Genes Into Tissues Of Living Mice By DNA-Coated Microprojectiles," *PNAS*, 88:2726-2729 (1991).

Wingo et al., "Cancer Statistics, 1995," *CA- A Cancer Journal for Clinicians*, 45(1):8-30 (1995).

Wodak, "Computer-Aided Design in Protein Engineering," *Annals of the New York Academy of Science*, 501:1-13 (1987).

Yu et al., "Establishment And Characterization Of Renal Cell Carcinoma Cell Lines With Multidrug Resistance," *Urology Research*, 28(2):86-92 (2000).

Zhang et al., "Glutathione-Related Mechanisms In Cellular Resistance To Anticancer Drugs (Review)," *International Journal of Oncology*, 12:871-882 (1998).


Zhu et al., "Functional Analysis of the Nucleotide Binding Domains of the Multidrug Resistance Protein (MRP)," *Oncology Research*, 9(5):229-236 (1997).

REMARKS

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application and (2) printed on any patent issuing from this application. Applicants also request that the Examiner initial the enclosed Form PTO/SB/08A in the appropriate places to indicate that the documents have been considered and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

This Statement is submitted more than three months from the application filing date, but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Statement to Deposit Account No. 06-1075, Order No. 003747-0082.

Respectfully submitted,

  
James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants

c/o FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
1251 Avenue of the Americas  
New York, New York 10020  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	1	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> - Number <sup>2</sup> - Kind Code <sup>3</sup>	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		WO 94/29469	12/22/94	PCT		
		WO 97/00957	01/09/97	PCT		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T <sup>6</sup>
		Anderson, "Human Gene Therapy", <i>Science</i> , 256:808-813 (1992).	
		Bakos et al., "Functional Multidrug Resistance Protein (MRP1) Lacking The N-Terminal Transmembrane Domain," <i>Journal of Biological Chemistry</i> , 273(27):32167-32175 (1998).	
		Berry et al., "A Prototype Computer System For <i>De Novo</i> Protein Design," <i>Biochemical Society Transactions</i> , 2(4):1033-1036 (1994).	
		Bertz et al., "Use of <i>In Vitro</i> and <i>In Vivo</i> Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions," <i>Clinical Pharmacokinetics</i> , 32(3):210-258 (1997).	
		Borst et al., "The Multidrug Resistance Protein Family," <i>Biochimica et Biophysica Acta</i> , 1461:347-357 (1999).	
		Borst et al., "A Family of Drug Transporters: The Multidrug Resistance-Associated Proteins," <i>Journal of National Cancer Institute</i> , 92(16):1295-1302 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/627,253	
				Filing Date	
				July 24, 2003; Conf. No. 4194	
				First Named Inventor	
				Ulrich Brinkmann et al.	
				Art Unit	
				1634	
				Examiner Name	
				Juliet Caroline Switzer	
				Attorney Docket Number	
				VOS/42 CON	
Sheet	2	of	10		

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Campling et al., "Expression of the <i>MRP</i> and <i>MDR1</i> Multidrug Resistance Genes in Small Cell Lung Cancer," <i>Clinical Cancer Research</i> , 3(1):115-122 (1997).	
		Chow et al. "Rising Incidence of Renal Cell Cancer in the United States," <i>JAMA</i> , 281(17):1628-1631 (1999).	
		Cole et al., "Multidrug resistance mediated by the ATP-binding cassette transporter protein <i>MRP</i> ," <i>BioEssays</i> , 20(11):931-940 (1998).	
		Cole et al., "Pharmacological Characterization of Multidrug Resistant <i>MRP</i> -transfected Human Tumor Cells," <i>Cancer Research</i> , 54:5902-5910 (1994).	
		Database EMBL Online EBI; Seq ID No.: 75, Database Accession No. AC026452, XP002217455 abstract (2000).	
		Database EMBL Online EBI; Database Accession No.: AC026452, Doe Joint Genome Institute: "Sequencing of Human Chromosome 16" XP002241553 for SEQ ID NOs: 171 and 172 Abstract (2000).	
		D'Hondt et al., "Retrovirus-Mediated Gene Transfer of the Multidrug Resistance-Associated Protein ( <i>MRP</i> ) cDNA Protects Cells from Chemotherapeutic Agents," <i>Human Gene Therapy</i> , 8(15):1745-1751 (1997).	
		Dörner et al., "The Synthesis of Peptidomimetic Combinatorial Libraries Through Successive Amide Alkylations," <i>Bioorganic and Medicinal Chemistry</i> , 4(5):709-715 (1996).	
		Engel et al., "Prediction of CYP2D6-Mediated Polymorphic Drug Metabolism (Sparteine Type) Based On In Vitro Investigations," <i>Journal of Chromatography B: Biomedical Applications</i> , 678:93-103 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	3	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Evers et al., "Inhibitory Effect Of The Reversal Agents V-104, GF120918 And Pluronic L61 On MDR1 Pgp-, MRP1- And MR2-Mediated Transport," <i>British Journal of Cancer</i> , 83(3):366-374 (2000).	
		Fassina et al., "Identification of Interactive Sites of Proteins and Protein Receptors by Computer-Assisted Searches for Complementary Peptide Sequences," <i>Immunomethods</i> , 5:114-120 (1994).	
		Filipits et al., "Immunocytochemical Detection Of The Multidrug Resistance-Associated Protein And P-Glycoprotein In Acute Myeloid Leukemia: Impact Of Antibodies, Sample Source And Disease Status," <i>Leukemia</i> , 11(7):1073-1077 (1997).	
		Flens et al., "Immunochemical Detection Of The Multidrug Resistance-Associated Protein MRP In Human Multidrug-Resistant Tumor Cells By Monoclonal Antibodies," <i>Cancer Research</i> , 54(17):4557-4563 (1994).	
		Galfre et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981).	
		Giordano et al., "Intracoronary Gene Transfer Of Fibroblast Growth Factor-5 Increases Blood Flow And Contractile Function In An Ischemic Region Of The Heart," <i>Nature Medicine</i> , 2(5):534-539 (1996).	
		Grant et al., "Analysis of the Intron-Exon Organization of the Human Multidrug-Resistance Protein Gene (MRP) and Alternative Splicing of Its mRNA," <i>Genomics</i> , 45(2):368-378 (1997).	
		Heath et al., Hypertension, Diuretics, and Antihypertensive Medications as Possible Risk Factors for Renal Cell Cancer," <i>American Journal of Epidemiology</i> , 145(7):607-613 (1997).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	4	of	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Heijn et al., "Anthracyclines Modulate Multidrug Resistance Protein (MRP) Mediated Organic Anion Transport," <i>Biochimica et Biophysica Acta</i> , 1326: 12-22 (1997).	
		Hipfner et al., "Monoclonal Antibodies that Inhibit the Transport Function of the 190-kDa Multidrug Resistance Protein, MRP," <i>Journal of Biological Chemistry</i> , 274(22):15420-15426 (1999).	
		Hipfner et al., "Detection of the Mr190,000 Multidrug Resistance Protein, MRP, with Monoclonal Antibodies," <i>Cancer Research</i> , 54(22):5788-5792.	
		Hipfner et al., "Membrane Topology of the Multidrug Resistance Protein (MRP)," <i>Journal of Biological Chemistry</i> , 272(38):23623-23630 (1997)	
		Hipfner et al. "Structural, Mechanistic And Clinical Aspects Of MRP1," <i>Biochimica et Biophysica Acta</i> , 1461:359-376 (1999).	
		Hoffman et al., "Rapid Protein Structure Classification Using One-Dimensional Structure Profiles On The Bioscan Parallel Computer," <i>CABIOS</i> , 11(6):675-679 (1995).	
		Hrycyna et al., Mechanism of Action of Human P-glycoprotein ATPase Activity," <i>Journal of Biological Chemistry</i> , 273(27):16631-16634 (1998).	
		Isner et al, "Clinical Evidence Of Angiogenesis After Arterial Gene Transfer Of phVEGF165 In Patient With Ischaemic Limb," <i>Lancet</i> , 348(10):370-374 (1996).	
		Jedlitschky et al., "ATP-Dependent Transport Of Bilirubin Glucuronides By The Multidrug Resistance Protein MRP-1 And Its Hepatocyte Canalicular Isoform MRP2," <i>Biochemical Journal</i> , 327:305-310 (1997).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	5	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

NON PATENT LITERATURE DOCUMENTS			
		Jounaïdi et al., "Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?," <i>Biochemical and Biophysical Research Communication</i> , 221:466-470 (1996).	
		Klein et al., "An Inventory Of The Human ABC Proteins," <i>Biochimica et Biophysica Acta</i> , 1461:237-262 (1999).	
		Kohler et al., "Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity," <i>Nature</i> , 256:495-497 (1975).	
		Levine, "Acquired Cystic Kidney Disease," <i>Radiologic Clinics of North America</i> , 34(5):947-964 (1996).	
		Linehan et al., "Identification of The Von Hippel-Lindau (VHL) Gene," <i>JAMA</i> , 273(7):564-570 (1995),	
		Loe et al., "ATP-Dependent Transport of Aflatoxin B1 and its Glutathione Conjugates by the Product of the Multidrug Resistance Protein (MRP) Gene," <i>Molecular Pharmacology</i> , 51(6):1034-1041 (1997).	
		Loftus et al., "Genome Duplications and Other Features in 12 MB of DNA Sequence from Human Chromosome 16p and 16q," <i>Genomics</i> , 60(3):295-308 (1999).	
		Longueux et al., "Candidate Genetic Modifiers of Individual Susceptibility to Renal Cell Carcinoma: A Study of Polymorphic Human Xenobiotic-Metabolizing Enzymes," <i>Cancer Research</i> , 59:2903-2908 (1999).	
		Machiels et al., "Retrovirus-Mediated Gene Transfer of the Human Multidrug Resistance-Associated Protein into Hematopoietic Cells Protects Mice from Chemotherapy-Induced Leukopenia," <i>Human Gene Therapy</i> , 10(5): 801-811 (1999).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	6	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Malmborg et al., "BIAcore As A Tool In Antibody Engineering," <i>Journal of Immunological Methods</i> , 183:7-13 (1995).	
		Marshall, "Getting The Right Drug Into The Right Patient," <i>Nature Biotechnology</i> , 15(12):1249-1252 (1997).	
		Marshall, "Laying The Foundations For Personalized Medicines," <i>Nature Biotechnology</i> , 15(10):954-957 (1997).	
		Meyer et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism," <i>Annual Review of Pharmacology and Toxicology</i> , 37:269-296 (1997).	
		Meyer, "Overview of Enzymes of Drug Metabolism," <i>Journal of Pharmacokinetics and Biopharmaceutics</i> , 24(5):449-459 (1996).	
		Monge et al., "Computer Modeling of Protein Folding: Conformational and Energetic Analysis of Reduced and Detailed Proteins Models," <i>Journal of Molecular Biology</i> , 247(5):995-1012 (1995).	
		Mouellic et al., "Targeted Replacement Of The Homeobox Gene <i>Hox-3.1</i> By The <i>Escherichia Coli LacZ</i> In Mouse Chimeric Embryos," <i>PNAS</i> , 87:4712-4716 (1990).	
		Mühlhauser et al., "VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," <i>Circulation Research</i> , 77:1077-1086 (1995).	
		Nooter et al., "Molecular Mechanisms of Multidrug Resistance in Cancer Chemotherapy," <i>Pathology Research and Practice</i> , 192(7):768-780 (1996).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	7	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Norris et al., "Expression Of The Gene For Multidrug-Resistance-Associated Protein And Outcome In Patients With Neuroblastoma," <i>New England Journal of Medicine</i> , 334(4):231-238 (1996).	
		Olszewski et al., "Folding Simulations and Computer Redesign of Protein A Three-Helix Bundle Motifs," <i>Proteins: Structure, Function, and Genetics</i> , 25(3):286-299 (1996).	
		Ostresh et al., "Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries," <i>Methods in Enzymology</i> , 267:220-234 (1996).	
		Ozama, "Strategic Proposals For Avoiding Toxic Interactions With Drugs For Clinical Use During Development And After Marketing Of A New Drug – Proposals For Designing Non-Clinical And Clinical Studies – Is The Non-Clinical Study Useful?," <i>Journal of Toxicological Sciences</i> , 21(5):323-329 (1996).	
		Pabo et al., "Computer-Aided Model-Building Strategies for Protein Design," <i>Biochemistry</i> , 25(20):5987-5991 (1986).	
		Perdu et al., "Identification of Novel Polymorphisms in the pM5 and MRP1 (ABCC1) Genes at Locus 16p13.1 and Exclusion of Both Genes as Responsible for Pseudoxanthoma Elasticum," <i>Human Mutation</i> , 17(1):74-75 (2001).	
		Priebe et al., "Doxorubicin – and Daunorubicin-Glutathione Conjugates, but not Unconjugated Drugs, Competitively Inhibit Leukotriene C4 Transport Mediated by MRP/GS-X Pump," <i>Biochemical and Biophysical Research Communication</i> , 247(3):859-863 (1998).	
		Ramsay, "DNA Chips: State-of-the Art," <i>Nature Biotechnology</i> , 16:40-44 (1998).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	8	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Rao et al., "Choroid Plexus Epithelial Expression Of <i>MDR1</i> P Glycoprotein And Multidrug Resistance-Associated Protein Contribute To The Blood-Cerebrospinal-Fluid Drug-Permeability Barrier," <i>PNAS</i> , 96:3900-3905 (1999).	
		Rappa et al., "New Insights into the Biology and Pharmacology of the Multidrug Resistance Protein (MRP) from the Gene Knockout Models," <i>Biochemical Pharmacology</i> , 58(4):557-562 (1999).	
		Renouf et al., "Molecular Modelling Of Glycoproteins By Homology With Non-Glycosylated Protein Domains, Computer Simulated Glycosylation And Molecular Dynamics," <i>Glycoimmunology</i> , 376:37-45 (1995).	
		Rose et al., "Three-Dimensional Structures of HIV-1 and SIV Protease Product Complexes," <i>Biochemistry</i> , 35:12933-12944 (1996).	
		Ross et al., "High level multiplex genotyping by MALDI-TOF mass spectrometry," <i>Nature Biotechnology</i> , 16:1347-1351 (1998).	
		Rutenber et al., "A New Class of HIV-1 Protease Inhibitor: The Crystallographic Structure, Inhibition and Chemical Synthesis of an Aminimide Peptide Isostere," <i>Bioorganic and Medicinal Chemistry</i> , 4(9):1545-1558 (1996).	
		Schaper et al., "Molecular Mechanisms of Coronary Collateral Vessel Growth," <i>Circulation Research</i> , 79:911-919 (1996).	
		Schaper et al., "Therapeutic Targets In Cardiovascular Disorders," <i>Current Opinion in Biotechnology</i> , 7(6):635-640 (1996).	
		Schier et al., "Efficient <i>In Vitro</i> Affinity Maturation Of Phage Antibodies Using Biacore Guided Selections," <i>Human Antibodies and Hybridomas</i> , 7(3):97-105 (1996).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	9	of	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Schlehofer et al., "International Renal-Cell-Cancer Study IV. The Role of Medical and Family History," <i>International Journal of Cancer</i> , 66(6):723-726 (1996).	
		Schneider et al., "ATP-Binding-Cassette (ABC) Transport Systems: Functional And Structural Aspects Of The ATP-Hydrolyzing Subunits/Domains," <i>FEMS Microbiology Reviews</i> , 22:1-20 (1998).	
		Shimer et al., "Ligase Chain Reaction," <i>Methods in Molecular Biology</i> , 46:269-278 (1995).	
		Stewart et al., "Reduction of Expression of the Multidrug Resistance Protein (MRP) in Human Tumor Cells by Antisense Phosphorothioate Oligonucleotides," <i>Biochemical Pharmacology</i> , 51(4):461-469 (1996).	
		Stride et al., "Pharmacological Characterization of the Murine and Human Orthologs of Multidrug-Resistance Protein in Transfected Human Embryonic Kidney Cells," <i>Molecular Pharmacology</i> , 52:344-353 (1997).	
		Sullivan et al., "The Expression of Drug Resistance Gene Products During the Progressional of Human Prostrate Cancer," <i>Clinical Cancer Research</i> , 4(6):1393-1403 (1998).	
		Takebayashi et al., "The Expression of Multidrug Resistance Protein in Human Gastrointestinal Tract Carcinomas," <i>Cancer</i> , 82(4):661-666 (1998).	
		Ueda et al., "How Does P-Glycoprotein Recognize Its Substrates?," <i>Seminars in Cancer Biology</i> , 8(3):151-159 (1997).	
		Walker et al., "Distantly Related Sequences In The A- And B-Subunits Of ATP Synthase, Myosin, Kinases And Other ATP-Requiring Enzymes And A Common Nucleotide Binding Fold," <i>The EMBO Journal</i> , 1(8):945-951 (1982).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/627,253
				<b>Filing Date</b>	July 24, 2003; Conf. No. 4194
				<b>First Named Inventor</b>	Ulrich Brinkmann et al.
				<b>Art Unit</b>	1634
				<b>Examiner Name</b>	Juliet Caroline Switzer
<b>Sheet</b>	10	<b>of</b>	10	<b>Attorney Docket Number</b>	VOS/42 CON

<b>NON PATENT LITERATURE DOCUMENTS</b>			
		Wang et al., "Second-Generation Adenovirus Vectors," <i>Nature Medicine</i> , 2(6):714-716 (1996).	
		West et al., "Interpatient Variability: Genetic Predisposition and Other Genetic Factors," <i>Journal of Clinical Pharmacology</i> , 37(7):635-648 (1997).	
		Wijnholds et al., "Increased Sensitivity To Anticancer Drugs And Decreased Inflammatory Response In Mice Lacking The Multidrug Resistance-Associated Protein," <i>Nature Medicine</i> , 3(11):1275-1279 (1997).	
		Williams et al., "Introduction Of Foreign Genes Into Tissues Of Living Mice By DNA-Coated Microprojectiles," <i>PNAS</i> , 88:2726-2729 (1991).	
		Wingo et al., "Cancer Statistics, 1995," <i>CA- A Cancer Journal for Clinicians</i> , 45(1):8-30 (1995).	
		Wodak, "Computer-Aided Design in Protein Engineering," <i>Annals of the New York Academy of Science</i> , 501:1-13 (1987).	
		Yu et al., "Establishment And Characterization Of Renal Cell Carcinoma Cell Lines With Multidrug Resistance," <i>Urology Research</i> , 28(2):86-92 (2000).	
		Zhang et al., "Glutathione-Related Mechanisms In Cellular Resistance To Anticancer Drugs (Review)," <i>International Journal of Oncology</i> , 12:871-882 (1998).	
		Zhu et al., "Functional Analysis of the Nucleotide Binding Domains of the Multidrug Resistance Protein (MRP)," <i>Oncology Research</i> , 9(5):229-236 (1997).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**